Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867)

Market Cap	15.30B
Revenue (ttm)	2.43B
Net Income (ttm)	341.31M
Shares Out	1.95B
EPS (ttm)	0.16
PE Ratio	49.18
Forward PE	41.32
Dividend	0.25 (3.10%)
Ex-Dividend Date	n/a

Volume	10,063,416
Open	8.22
Previous Close	8.20
Day's Range	8.13 - 8.23
52-Week Range	7.02 - 11.09
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 30, 2025

About Tonghua Dongbao Pharmaceutical

Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China. It offers human insulin API and injections; insulin glargine API and injections; insulin aspart API and injections; liraglutide injections; zhennaoning capsules; and diabetes-related medical devices. The company also provides insulin pen and needle injection system, blood sugar monitoring system, and online and offline patient managem...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 3,196
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600867

Financial Performance

In 2023, Tonghua Dongbao Pharmaceutical's revenue was 3.08 billion, an increase of 10.69% compared to the previous year's 2.78 billion. Earnings were 1.17 billion, a decrease of -26.17%.